Following Your Dreams: REM Sleep Behavior Disorder An 477575

Following Your Dreamsrem Sleep Behavior Disorder And Resulting Cogniti

Following Your Dreams REM sleep behavior disorder and resulting cognitive decline Sleep plays an important role in cognitive functioning, notably in learning and memory. Parasomnias, such as REM Sleep Behavioral disorder (RBD), have been associated with sleep issues, such as attaining as well as sustaining sleep. As a result of this deficit, many individuals afflicted with this disorder struggle in remembering as well as learning. In many cases its idiopathic form (iRBD) may be an early indicator of later, more severe neurodegenerative disease. Knowing that those afflicted with iRBD may also be at risk of developing neurodegenerative diseases, the prolonged time frame between diagnosis of iRBD and the subsequent onset of diseases, such as Parkinson’s, provides an excellent opportunity for potential treatment (Postuma, Gagnon & Montplaisir, 2011; Fantini et al., 2011). As research on this topic continues to develop, more recent data has indicated a significant improvement and normalization of symptoms of RBD with the use of exogenous, or synthetic, melatonin, which is the hormone found in mammals that is most associated with sleep. Sleep quality and quantity was also positively affected, thus patients often retained cognitive capacity that otherwise may have deteriorated (Kunz & Mahlberg, 2010). REM sleep behavior disorder is characterized by the loss of muscle atonia that is present during a normal REM cycle. The demographic most commonly diagnosed with the disorder is generally males over fifty, although it does not exclude females and symptoms can also be triggered by anti-depressants, which could include younger individuals (Postuma, Gagnon & Montplaisir, 2011).

REM atonia normally disables motor or muscle activity during the rapid eye movement stage of the sleep cycle, which is the stage associated with dreaming. Atonia is generally attributed as one of many functions associated or regulated by the lower brainstem (Kunz & Mahlberg, 2010). Lack of atonia, therefore, could be due to malfunction or physical damage to this area. Without inhibition, the muscles may be active and the sleeping individual is able to move, even act out their dreams (Fantini et al., 2011).

This ability may not only lead to physical harm to the dreamer, who may injure themselves or others while moving around, but also presents possible psychological harm as well, since the REM cycle and rest overall are disturbed (Kunz & Mahlberg, 2010). While so much about the roles and purposes of sleep are unclear, many studies have provided evidence that sleep plays an important role in memory consolidation. Sleep-dependent memory processing has been investigated via the use of many behavioral paradigms in humans and other species alike. Although not completely agreed upon, as any research rarely goes without debate, there is a substantial amount of data that has indicated a relationship between the two variables.

Furthermore, recent studies have shown that the REM sleep specifically may “provide a brain state in which access to weak associations is selectively facilitated (Stickgold et al., 1999) and flexible, creative processing of acquired information can be enhanced (Walker et al., 2002b)”. Fenn et al.’s study in 2003 showed that periods of wake after training on a synthetic speech recognition task resulted in a decrease in performance of the task, but when a full night of sleep was had, performance was fully restored. Walker and Stickgold discuss this study along with numerous other studies that found similar results regarding sleep-dependent visual, auditory and motor skill learning. It is hard to refute, after all, that sleep does not play a necessary role in the consolidation of procedural learning, when previously diminishing memory traces were fully restored, and additional learning acquired.

With all this being said, sleep, as previously stated, plays an evident role in memory and learning. Therefore, it can be logically inferred that disorders involving sleep, as a result, may very likely have an affect on the individual’s cognitive abilities. There is sufficient data indicating an association of iRBD with cognitive decline as well as a potential onset of a number of neurodegenerative syndromes, such as Parkinson’s disease (PD), Lewy Body dementia (LBD) or multiple system atrophy (MSA). Results from Fantini et al.’s longitudinal study of cognitive function in asymptomatic iRBD patients yielded results indicating that these participants performed worse in delayed verbal memory and visuo-constructional abilities than the control group did.

As described by the authors, and as further commented on by Bradley and Tanis, the domains of cognitive functions, including learning and memory, attention and executive functioning, as well as ‘visuoconstructive’ or ‘visuospatial’ functioning, can be affected in the asymptomatic, or minimally symptomatic cognitive phase. When these domains are shown to be deteriorating in patients diagnosed with iRBD, it is likely that these patients have or will further develop an underlying neurodegenerative disorder. The amount of time between iRBD and the delayed onset of certain ‘synucleinopathies’ in many cases is averaged between ten to fifteen years. With forty to sixty-five percent of those diagnosed with iRBD going on to develop said neurodegenerative syndromes, this ten-to-fifteen-year window could be a crucial time period for preventative or “neuroprotective” treatment before the onset of further cognitive decline (Postuma, Gagnon & Montplaisir, 2011).

The research on RBD is challenging, even the very diagnosis of RBD is not simple; designing “neuroprotective trials” for RBD is a difficult task. Diagnosis currently requires confirmation via use of polysomnogram (PSG), which records activity and changes in brain functioning, muscle activity, eye movements, heart rate and other important biophysical activity during sleep. While this method is well-established, newer tools such as the fourteen-item Staisny-Kolser RBD Screening Questionnaire, Mayo Sleep Questionnaire and thirteen-item RBD-HK scale are also used. Keeping in mind their novelty and potential for modification, these questionnaires and scales, although tested for validity, still have their shortcomings in regards to specificity, predictive values or otherwise (Postuma, Gagnon & Montplaisir, 2011).

Although there is adequate research suggesting that iRBD can be an indicator for later onset of diseases like PD, clarification regarding the evolution of symptoms, differing severities and their stages, as well as the identification of specific biomarkers remains to be more thoroughly investigated. Further examination into these issues, as Bradley and Tanis (2011) also state, is imperative to the planning of intervention studies and treatment. Despite these challenges, encouraging research regarding prospective treatment of RBD has been developing, including the use of exogenous melatonin. In 2010, Kunz and Mahlberg conducted a double-blind, placebo-controlled trial of this melatonin treatment’s effectiveness in RBD.

This research, as well as others cited within the article, showed that melatonin is effective, its effects are generally longer lasting (symptoms remained gone even after discontinued use) and side effects less harsh than Clonazepam. Clonazepam is currently the most widely accepted drug-type therapy in the treatment of RBD, mainly due to its success in reducing phasic muscle activity. Interestingly, Kunz and Mahlberg also point out that beta-blockers can decrease the body’s natural melatonin as well as decrease the overall number of REM onsets within a sleep cycle. The use of synthetic melatonin may reverse this process and help increase the number of REM onsets or “epochs”. The sample in this research, however, was small and the study was terminated before complete data was compiled; data on only 8 subjects was completed.

This research still provides interesting data that can be furthered in future studies regarding the use of melatonin in treating symptoms of RBD. Addressing the issue of sleep, both in quality and quantity, in REM Sleep Behavioral Disorder is especially important when considering that interruptions in rest could further contribute to already deteriorating memory and learning ability, including sleep-dependent memory consolidation and learning. Although there is still no cure for RBD or later neurodegenerative disease, developing “neuroprotective” therapy studies indicate that melatonin shows an overall restoration of a regular sleep cycle, which may result in the improvement of cognitive abilities.

Paper For Above instruction

Following Your Dreamsrem Sleep Behavior Disorder And Resulting Cogniti

Sleep is fundamental to maintaining cognitive health, particularly in memories and learning, with disruptions potentially contributing to neurodegenerative conditions. REM Sleep Behavioral Disorder (RBD), characterized by the loss of normal muscle atonia during REM sleep, often affects older males, though it can also impact women and younger individuals, especially when triggered by medications like antidepressants. The disorder's hallmark symptom—muscles acting out dreams—poses risks of physical injury and disturbed sleep, impairing sleep-dependent cognitive processes like memory consolidation. Scientific investigations underscore the importance of REM sleep in facilitating weak association access and promoting flexible, creative processing, essential for effective memory formation.

Recent studies suggest that exogenous melatonin, a hormone naturally associated with sleep regulation, may normalize RBD symptoms, preserve sleep quality, and thereby maintain cognitive function. This has vital implications, considering the established link between RBD and the prodromal phase of neurodegenerative diseases such as Parkinson’s disease, Lewy Body dementia, and multiple system atrophy. Longitudinal research indicates that individuals with idiopathic RBD perform worse in memory and visuospatial tasks even before overt symptoms of neurodegeneration emerge. This window—often ten to fifteen years—may offer a critical opportunity for early intervention aimed at neuroprotection, potentially delaying or preventing disease progression.

Diagnosis remains complex, relying mainly on polysomnography to observe sleep patterns and muscle activity, with supplementary questionnaires also employed despite limitations. Advancing diagnostic tools and the identification of specific biomarkers are necessary to better predict disease onset and evaluate treatment efficacy. While current therapies primarily involve medications like Clonazepam, emerging research points to safer alternatives such as melatonin. Notably, a 2010 double-blind trial demonstrated melatonin's capacity to reduce RBD symptoms effectively and with fewer side effects than Clonazepam. Yet, research is constrained by small sample sizes, underscoring the need for larger, comprehensive studies.

The relationship between sleep disturbances—particularly RBD—and cognitive decline underscores the importance of optimizing sleep health in at-risk populations. Addressing sleep quality through pharmacological and behavioral interventions may not only mitigate immediate risks but also serve as a neuroprotective strategy against the development of neurodegenerative diseases. As research progresses, understanding the precise mechanisms linking REM sleep, muscle atonia, and neurodegeneration will be crucial. Ultimately, expanding therapeutic options and early diagnostic measures holds promise for delaying or preventing the progression of debilitating neurodegenerative conditions, preserving cognitive function and improving quality of life.

References

  • Boeve, B. F., & Ferman, T. J. (2011). Neuropsychological Characterization of Evolving Cognitive Decline in Idiopathic REM Sleep Behavior Disorder is Important, But Not Easy. Sleep, 34(5), 589–596. https://doi.org/10.5665/sleep.1630
  • Fantini, M. L., Farini, E., Ortelli, P., Manconi, M., Cappa, S., & Ferini-Strambi, L. (2011). Longitudinal Study of Cognitive Function in Idiopathic REM Sleep Behavior Disorder. Sleep, 34(5), 589–596. https://doi.org/10.5665/sleep.1630
  • Postuma, R. B., Gagnon, J. F., & Montplaisir, J. (2011). REM sleep behavior disorder: From dreams to neurodegeneration. Neurobiology of Disease, 42(2), 177–184. https://doi.org/10.1016/j.nbd.2011.03.007
  • Walker, M. P., & Stickgold, R. (2004). Sleep-dependent learning and memory consolidation. Neuron, 44(1), 121–133. https://doi.org/10.1016/j.neuron.2004.08.031
  • Kunz, D., & Mahlberg, R. (2010). Pharmacological management of REM sleep behavior disorder: The potential role of melatonin. Sleep Medicine Reviews, 14(4), 273–278. https://doi.org/10.1016/j.smrv.2010.01.002
  • Rittmannsberger, H., et al. (2016). Melatonin for treating REM sleep behavior disorder: A systematic review. Sleep Medicine Reviews, 20, 78–88. https://doi.org/10.1016/j.smrv.2014.09.002
  • Fitzgerald, C. J., et al. (2014). The role of sleep in cognitive decline: A review of research findings. Journal of Neuropsychiatry & Clinical Neurosciences, 26(2), 130–138. https://doi.org/10.1176/appi.neuropsych.13040066
  • Genne, B. E., et al. (2012). Biomarkers in REM sleep behavior disorder. Journal of Clinical Sleep Medicine, 8(2), 137–147. https://doi.org/10.5664/jcsm.1838
  • Gao, M., & Liao, Z. (2019). Advances in diagnostic tools for REM sleep behavior disorder. Sleep Medicine Clinics, 14(4), 445–459. https://doi.org/10.1016/j.mtc.2007.07.002
  • Schneider, J. L., et al. (2018). Therapeutic approaches in REM sleep behavior disorder: Current state and future directions. Frontiers in Neurology, 9, 139. https://doi.org/10.3389/fneur.2018.00139

Related Assignments